S100鈣結(jié)合蛋白A9(S100A9)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for S100 Calcium Binding Protein A9 (S100A9)
MRP14; MIF; 60B8AG; CFAG; NIF; CAGB; CGLB; L1AG; P14; Calgranulin B; Migration inhibitory factor-related protein 14; Calprotectin L1H subunit; Leukocyte L1 complex heavy chain
- 編號(hào)USEB793Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長3h
- 檢測(cè)范圍15.6-1,000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于5.5pg/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1397 ¥ 1995 ¥ 8978 ¥ 16958 ¥ 139650
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)S100鈣結(jié)合蛋白A9(S100A9)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的S100鈣結(jié)合蛋白A9(S100A9)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 91-105 | 94 |
| EDTA plasma(n=5) | 80-90 | 81 |
| heparin plasma(n=5) | 89-97 | 93 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的S100鈣結(jié)合蛋白A9(S100A9)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中S100鈣結(jié)合蛋白A9(S100A9)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 95-103% | 93-105% | 78-98% | 80-96% |
| EDTA plasma(n=5) | 85-102% | 81-88% | 95-104% | 85-104% |
| heparin plasma(n=5) | 86-101% | 91-105% | 78-92% | 97-104% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將S100鈣結(jié)合蛋白A9(S100A9)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的S100鈣結(jié)合蛋白A9(S100A9)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的S100鈣結(jié)合蛋白A9(S100A9)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的S100鈣結(jié)合蛋白A9(S100A9)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| J. Proteome Res. | Differential Proteomic Analysis Distinguishes Tissue Repair Biomarker Signatures in Wound Exudates Obtained from Normal Healing and Chronic Wounds [Pubmed: source] |
| Biochemical and Biophysical Research Communications | High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice [ScienceDirect: S0006291X1200352X] |
| PLoS One. | Proteins with Altered Levels in Plasma from Glioblastoma Patients as Revealed by iTRAQ-Based Quantitative Proteomic Analysis [PubMed: 23029420] |
| Mainz | Identifizierung neuer potentieller Biomarker für das Kolonkarzinom sowie dessen Vorstufen [Info:Source] |
| PLOS ONE | Susceptibility to COPD: Differential Proteomic Profiling after Acute Smoking [Pubmed:25036363] |
| the faseb journal | Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation [PubMed: 25934702] |
| Sci Rep.? | S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine [pmc:PMC4810364] |
| Journal?of?Alzheimer's?Disease | Proteomics?Analysis?of?Blood?Serums?from?Alzheimer's?Disease?Patients?Using?iTRAQ?LabelingTechnology. [pubmed:27911324] |
| International journal of molecular sciences | Immune Modulating Topical S100A8/A9 Inhibits Growth of Pseudomonas aeruginosa and Mitigates Biofilm Infection in Chronic Wounds. [pubmed:28672877] |
| Gastroenterology | Tu1938-Micronutrients Assessment in Patients with Cirrhosis [10.1016:S0016-5085(18)33544-3] |
| Gastroenterology | Tu1942-PI3K/AKT-Mediated Upregulation of C7 Inhibits Colorectal Cancer Proliferation and Metastasis [10.1016:S0016-5085(18)33544-5] |
| Journal of Biological Chemistry | Signaling between pancreatic β-cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammation [Pubmed:29496993] |
| Cancer?Management and?Research | The role of calgranulin B gene on the biological behavior of squamous cervical cancer in vitro and in vivo [Pubmed:29497331] |
| European?review for?medical?and pharmacological?sciences | S100A8/A9 promotes MMP-9 expression in the fibroblasts from cardiac rupture after myocardial infarction by inducing macrophages secreting TNFα. [Pubmed:29949169] |
| Estudio de células inmunosupresoras y biomarcadores circulantes en carcinoma renal [] | |
| Lung | Mass Spectrometry Analysis of the Exhaled Breath Condensate and Proposal of Dermcidin and S100A9 as Possible Markers for Lung Cancer Prognosis [Pubmed: 31115649] |
| 中國醫(yī)藥導(dǎo)報(bào) | 降鈣素原, 超敏C 反應(yīng)蛋白, 紅細(xì)胞沉降率及S100A9 對(duì)肺結(jié)核合并肺部細(xì)菌感染的影響 [] |
| scandinavian journal of clinical & laboratory investigation | Serum S100A6, S100A8, S100A9 and S100A11 proteins in colorectal neoplasia: results of a single centre prospective study [Pubmed: 31856598] |
| PLoS One | Adverse reproductive effects of S100A9 on bovine sperm and early embryonic development in vitro [Pubmed: 31945120] |
| Sci Rep | Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate [34045609] |
| university of copenhagen | Adjunctive S100A8/A9 Immunomodulation Hinders Cipro fl oxacin Resistance in [] |
